Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database.
D000328:Adult; D000368:Aged; D001569:Benzodiazepines / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis / Q000706:statistics & numerical data; D016208:Databases, Factual / Q000706:statistics & numerical data*; D005260:Female; D017048:Health Care Costs / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D018967:Risperidone / Q000191:economics* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy* / Q000191:economics*; D018709:Statistics, Nonparametric; D014481:United States
D001569:Benzodiazepines; D018967:Risperidone; D000077152:Olanzapine